Physician profile
Elham Daneshvar
NPI 1619377132
$2,356.64
in general payments reported to CMS, 2019-2025
13 companies · $547 in 2025
The $547 reported for 2025 was more than what 79% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $204 · 2021: $141 · 2022: $293 · 2023: $283 · 2024: $309 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,110 · Entertainment: $29.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,110.35 |
| Entertainment | $29.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $563.99 | 2019-2025 | Acuvue |
| Coopervision INC. | $527.16 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $316.40 | 2019-2020 | |
| Alcon Vision LLC | $251.27 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $210.84 | 2022-2024 | Infuse, Biotrue |
| Tarsus Pharmaceuticals, INC. | $137.81 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $96.94 | 2024 | Omni Surgical System |
| Biotissue Holdings INC. | $92.18 | 2025 | |
| Allergan, INC. | $50.00 | 2019 | |
| Apellis Pharmaceuticals, INC. | $46.36 | 2025 | Syfovre |
| Optos, INC. | $29.25 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Carl Zeiss Meditec Ag | $17.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elham Daneshvar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.